<DOC>
	<DOCNO>NCT01285245</DOCNO>
	<brief_summary>The purpose study test whether anakinra able reduce insulin resistance . This test overweighted type I diabetes mellitus patient , residual beta-cell function . By use patient group , positive effect glycemic control consequence improve insulin sensitivity .</brief_summary>
	<brief_title>Effect Anakinra Insulin Sensitivity Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>Although typically associate type 2 diabetes , insulin resistance document Type 1 diabetes . Insulin resistance may also play important role pathophysiology type 1 diabetes mellitus . Once diabetes emerge chronically elevate glucose level induce insulin resistance ( glucose toxicity ) . Inflammation important link obesity insulin resistance . The mechanism hyperglycemia-induced insulin resistance clear , evidently must relate high glucose level . There indication chronic hyperglycemia induce inflammation , example hyperglycemia induce IL-1β release , recent study show interaction thioredoxin interact protein ( TXNIP ) , level beta-cell also , find group , level adipose tissue All together , finding suggest block IL-1β-receptor activation interleukin-1 receptor antagonist anakinra , may reverse insulin resistance associate obesity and/or chronic hyperglycemia . When apply ( hyperglycemic ) subject type 2 diabetes , block IL-1β diminish effect glucose toxicity level beta-cell function level insulin sensitivity . When apply ( hyperglycemic ) subject type 1 diabetes , effect glucose toxicity level insulin sensitivity decrease . In order able study isolate effect IL-1β blockade insulin sensitivity , study test hypothesis subject type 1 diabetes hence provide proof principle vivo human propose link hyperglycemia , inflammation insulin resistance .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Type 1 diabetes 5 year Body mass index &gt; 25 kg/m2 Insulin requirement &gt; 0.5 U/kg bodyweight HbA1c &gt; 7.5 % , stable glycemic control Inability give inform consent Presence medical condition might interfere current study protocol . Immunodeficiency immunosuppressive treatment ( include TNFα block agent corticosteroid ) Antiinflammatory drug ( include nonsteroidal antiinflammatory drug , 100 mg less aspirin per day allow ) Signs current infection ( fever , Creactive protein ( CRP ) &gt; 30 mmol/l , treatment antibiotic , previous current diagnosis tuberculosis . A history recurrent infection Pregnancy breastfeeding ( contraception least 3 month inclusion require fertile woman ) Liver disease ( aspartate aminotransferase alanine aminotransferase level three time upper limit normal range ) Renal disease ( creatinine &gt; 130 µmol/l Neutropenia &lt; 2 x 109/l</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>insulin sensitivity</keyword>
	<keyword>interleukin-1 receptor antagonist</keyword>
	<keyword>inflammation</keyword>
	<keyword>hyperglycemia-induced insulin resistance</keyword>
</DOC>